## Benefits of Participation: **PATIENTS**

## **SGLT2 Inhibitors & GLP1 Receptor Agonists**

The Michigan Collaborative for Type 2 Diabetes represents a paradigm shift in how we care for patients. Instead of focusing on minimizing complications, we are aiming to prevent and reverse Type 2 Diabetes. The initiatives that MCT2D will implement will result in benefits to the overall health of patients, in addition to putting them on the path to reversing their disease.



- Results in significant weight loss while insulin results in weight gain.
- Reduces heart failure hospitalizations, progression of CKD, and reduce cardiovascular outcomes (stroke, heart attack, and cardiovascular death) in people with high cardiovascular risk.
- Provides kidney protection benefits.
- Well tolerated SGLT2-I can replace need for injecting insulin. GLP1-RA may be injected once weekly instead of daily insulin.
- Lowers risk of hypoglycemia, and glucose variability compared to insulin.
- SGLT2 inhibitors may also promote modest improvements in blood pressure and blood cholesterol levels

## **Continuous Glucose Monitoring**



- Enhances patient understanding of how diet, exercise, stress, and daily routine impact blood glucose.
- Can result in a statistically significant A1c reduction with no medication adjustment.
- Identifies glycemic variability (peaks and valleys) to adjust diet and tailor medication regiment.
- Identifies episodes of low and high glucose before symptoms appear and identifies hypoglycemia unawareness.
- Decreases or removes need to test via finger pokes.
- Lowers risk of hypoglycemia, and glucose variability compared to insulin.

## Low Carbohydrate Diets



- Reduces post-prandial glucose spikes.
- Reduces insulin requirements.
- Reduces natural insulin, leading to reduced insulin resistance.
- Results in weight loss without excessive hunger.
- Reduces blood pressure.
- Reduces triglycerides.
- Increases HDL cholesterol.
- Favorable changes in self-reported measures of energy level, hunger and food cravings



Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM's Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit valuepartnerships.com. The opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.